Clinical trial
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing
NCT04578639 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing
- Lead sponsor
- Haukeland University Hospital
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 2, 2020
- Completion date
- September 14, 2025
- Enrollment
- 214 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing remitting multiple sclerosis